Item 5. Other Information
Item 5. OTHER INFORMATION
Not applicable.
Pacira BioSciences, Inc. | Q1 2023 Form 10-Q | Page 44
Table of Contents
Item 6. EXHIBITS
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
10.1
Executive Employment Agreement, dated June 17, 2019, between the Registrant and Daryl Gaugler.* †
10.2
Executive Employment Agreement, dated December 6, 2016, between the Registrant and Anthony Molloy.* †
10.3
Credit Agreement, dated March 31, 2023, among Pacira BioSciences, Inc., the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 3, 2023).
31.1
Certification of Chief Executive Officer and Chairman pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
31.2
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
32.1
Certification of Chief Executive Officer and Chairman and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive (Loss) Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*
104 Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Furnished herewith.
† Denotes management contract or compensatory plan or arrangement.
Pacira BioSciences, Inc. | Q1 2023 Form 10-Q | Page 45
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Date: May 3, 2023 By: /s/ DAVID STACK
David Stack
Chief Executive Officer and Chairman
(Principal Executive Officer)
Date: May 3, 2023 By: /s/ CHARLES A. REINHART, III
Charles A. Reinhart, III
Chief Financial Officer
(Principal Financial Officer)
Pacira BioSciences, Inc. | Q1 2023 Form 10-Q | Page 46
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.